Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

On May 29, analysts at Stifel raised their price target for Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) from $78 to $94 while ...

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...

As a result, a market for cheaper, off-brand versions of their active ingredients — semaglutide and tirzepatide — has ...

The percentage of adult patients with a diagnosis of overweight or obesity increased from 10.4% in 2019 to 15.7% in 2024.

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

The FDA has approved the first at-home cervical cancer test and weight loss drugs could reduce obesity related cancers.

A growing number of obese adults and children have been prescribed Ozempic or similar medications to lose weight ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...